During the past decade, Onkologische Schwerpunktpraxis conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis" #1 sponsor was "University of Heidelberg Medical Center" with 2 trials, followed by "Daiichi Sankyo, Inc." with 1 trials sponsored, "Fondazione Michelangelo" with 1 trials sponsored, "Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest" with 1 trials sponsored and "Mario Negri Institute for Pharmacological Research" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Averion International Corporation" with 1 trials as a collaborator, "Celgene" with 1 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator and "NSABP Foundation Inc" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Onkologische Schwerpunktpraxis" are "Breast Cancer" (2 trials), "Multiple Myeloma" (2 trials), "HER 2 Negative Breast Cancer" (1 trials), "HER2-Positive Primary Breast Cancer" (1 trials) and "Hormone Receptor Positive Tumor" (1 trials). Many other conditions were trialed in "Onkologische Schwerpunktpraxis" in a lesser frequency.

Most popular intervention types in "Onkologische Schwerpunktpraxis" are "Drug" (5 trials), "Combination Product" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bortezomib" (2 trials), "Dexamethasone" (2 trials), "Lenalidomide" (2 trials), "Abraxane" (1 trials) and "Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Onkologische Schwerpunktpraxis" are 4 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Onkologische Schwerpunktpraxis". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Onkologische Schwerpunktpraxis, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Onkologische Schwerpunktpraxis, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".